



Jessica Baker Flechtner, Ph.D. joined Genocea in 2007, soon after the company was founded, and currently serves as the chief scientific officer. Dr. Flechtner is a pioneer in the development of novel vaccines directed toward T cell immunity, and has more than 20 years of experience in immunology, infectious disease, cancer, and vaccine development. She leads Genocea's efforts to develop T cell-directed vaccines and immunotherapies against infectious diseases and other indications. Jessica has extensive experience fundraising from private and public firms, expanding a small company pipeline through strategic use of non-dilutive funding, and marketing to public investors for an IPO. Prior to joining Genocea, Dr. Flechtner developed vaccines and immunotherapies for cancer, infectious disease, autoimmunity and allergy in several companies including Mojave Therapeutics and Antigenics Inc. (now Agenus). She is an inventor on multiple pending issued patents and has numerous peer-reviewed scientific publications. Dr. Flechtner performed her post-doctoral work at the Dana Farber Cancer Institute and Harvard Medical School. She holds a Ph.D. in Cellular Immunology and a B.S. in Animal Science from Cornell University.